Biomea Shares Rise After Completing Enrollment in Diabetes Trial

MT Newswires Live

16 hours ago

Biomea Fusion (BMEA) shares rose over 14% in Monday trading after the firm said it has completed enrollment in a phase 2 trial of icovamenib in insulin-deficient Type 2 diabetes patients.

The clinical-stage firm said topline 26-week primary endpoint data from the COVALENT-211 trial is expected in Q1 of 2027.

Biomea also said COVALENT-212 mid-stage trial enrollment is still ongoing, with topline 26-week primary endpoint data anticipated in Q2 of 2027.

Price: 1.57, Change: +0.20, Percent Change: +14.60

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/news/2662203426"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662203426\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662203426?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-25 02:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662203426","market":"sg","top_or_hot":-1,"title":"Biomea Shares Rise After Completing Enrollment in Diabetes Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BMEA\">Biomea Fusion</a> (BMEA) shares rose over 14% in Monday trading after the firm said it has completed enrollment in a phase 2 trial of icovamenib in insulin-deficient Type 2 diabetes patients.</p><p>The clinical-stage firm said topline 26-week primary endpoint data from the COVALENT-211 trial is expected in Q1 of 2027.</p><p>Biomea also said COVALENT-212 mid-stage trial enrollment is still ongoing, with topline 26-week primary endpoint data anticipated in Q2 of 2027.</p><p>Price: 1.57, Change: +0.20, Percent Change: +14.60</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biomea Shares Rise After Completing Enrollment in Diabetes Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiomea Shares Rise After Completing Enrollment in Diabetes Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-25 02:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BMEA\">Biomea Fusion</a> (BMEA) shares rose over 14% in Monday trading after the firm said it has completed enrollment in a phase 2 trial of icovamenib in insulin-deficient Type 2 diabetes patients.</p><p>The clinical-stage firm said topline 26-week primary endpoint data from the COVALENT-211 trial is expected in Q1 of 2027.</p><p>Biomea also said COVALENT-212 mid-stage trial enrollment is still ongoing, with topline 26-week primary endpoint data anticipated in Q2 of 2027.</p><p>Price: 1.57, Change: +0.20, Percent Change: +14.60</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2662203426","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662203426","pubTimestamp":1787597276,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biomea Fusion  shares rose over 14% in Monday trading after the firm said it has completed enrollment in a phase 2 trial of icovamenib in insulin-deficient Type 2 diabetes patients.The clinical-stage firm said topline 26-week primary endpoint data from the COVALENT-211 trial is expected in Q1 of 2027.Biomea also said COVALENT-212 mid-stage trial enrollment is still ongoing, with topline 26-week primary endpoint data anticipated in Q2 of 2027.Price: 1.57, Change: +0.20, Percent Change: +14.60","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BMEA":"Biomea Fusion, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Biomea 完成糖尿病试验入组后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMEA":1},"content_text":"Biomea Fusion (BMEA) shares rose over 14% in Monday trading after the firm said it has completed enrollment in a phase 2 trial of icovamenib in insulin-deficient Type 2 diabetes patients.The clinical-stage firm said topline 26-week primary endpoint data from the COVALENT-211 trial is expected in Q1 of 2027.Biomea also said COVALENT-212 mid-stage trial enrollment is still ongoing, with topline 26-week primary endpoint data anticipated in Q2 of 2027.Price: 1.57, Change: +0.20, Percent Change: +14.60","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}